Robert Geho of Diasome, a T1DExchange member organization, participated in a live interview on TuDiabetes in May 2014. Current research in the role of the liver in normal glucose control demonstrates that the liver’s hepatocytes routinely store from 30% to as much as 60% of the glucose consumed each day. Because hepatic glucose storage and release are dependent on signaling from insulin and other hormones, this webinar explored both on the role of the liver in healthy individuals and on the effect of liver-targeted insulin in people with type 1 and type 2 diabetes. The video can be viewed below.

Robert Geho is a co-founder and CEO of Diasome Pharmaceuticals, Inc., focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. In his role at Diasome, he leads the management and strategic direction of the Company’s targeted insulin therapies, novel type 2 diabetes technologies, and oral therapy for obesity.  In addition to his responsibilities at Diasome, he is a co-founder and director of SDG, Inc., a nanotechnology therapeutics company that is an Equity Partner Company of the Cleveland Clinic Foundation in Cleveland, Ohio. Mr. Geho has led or co-led multiple rounds of financing for several biotechnology companies, and he has been a key participant in the formation of multiple life sciences focused companies. He received both his undergraduate degree and an MBA from Case Western Reserve University. Mr. Geho also serves as a member of the board of directors of the Diabetes Hands Foundation.